跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 19,689 条关于
“FLT3-ITD AML”
全部
19,689
临床试验
12,096
药物
1,786
机构
3,865
资讯
1,942
5个月前
Quizartinib Combination Therapy Shows Promise in Phase II Trial for FLT3-ITD AML
去年
LeukoStrat® CDx FLT3 Mutation Assay Receives EU Approval for AML Treatment Selection
去年
Daiichi Sankyo's Vanflyta Enters Phase 3 Trial for FLT3-ITD Negative AML
去年
CAR-T Therapy Yescarta and Quizartinib Approved for Blood Cancers on NHS Scotland
11个月前
Swissmedic Approves Two Orphan Drugs for Rare Cancers: Ayvakyt for GIST and Mastocytosis, VANFLYTA for FLT3-ITD AML
去年
Invivoscribe's LeukoStrat CDx FLT3 Mutation Assay Receives Regulatory Approval in UK and Switzerland
去年
RSK1 Inhibitor PMD-026 Shows Promise in Treating Blood Cancers in Addition to Breast Cancer
去年
Qurient Initiates Phase 1 Trial of Adrixetinib for Relapsed/Refractory AML
去年
Molecular Profiling Transforms AML Treatment Strategy as MRD Testing Guides Transplant Decisions
去年
Invivoscribe's LabPMM Secures New York State Approval for Ultra-Sensitive FLT3 ITD MRD Assay in AML
第 1 页,共 195 页
上一页
下一页